Amgen (AMGN) Invested Capital (2009 - 2026)

Amgen's Invested Capital history runs 16 years deep, the most recent figure standing at $5.4 billion for Q1 2026.

• In Q1 2026, Invested Capital rose 61.43% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at $14.6 billion (down 8.49% YoY), while the FY2025 annual figure was $4.6 billion, up 29.55% from the prior year.
• Invested Capital for Q1 2026 stood at $5.4 billion, up from $4.6 billion in the prior quarter.
• The five-year high for Invested Capital was $5.5 billion in Q2 2024, with the low at $817.0 million in Q2 2022.
• The 5-year median for Invested Capital is $2.2 billion (2023), against an average of $2.7 billion.
• Peak annual rise in Invested Capital reached 1728.74% in 2022, while the deepest fall reached 81.11% in 2022.
• Amgen's Invested Capital stood at $1.6 billion in 2022, then retreated by 9.3% to $1.4 billion in 2023, then surged by 146.02% to $3.6 billion in 2024, then grew by 29.55% to $4.6 billion in 2025, then advanced by 18.22% to $5.4 billion in 2026.
• Business Quant data shows AMGN's Invested Capital at $5.4 billion in Q1 2026, $4.6 billion in Q4 2025, and $2.2 billion in Q3 2025.